Omeros (OMER) is Amongst The Best Names Under $10 That Could Yield More Than 200% Return

Omeros Corp. (NASDAQ:OMER) is one of the 10 best stocks under $10 that could triple.

On June 26, Omeros Corp. (NASDAQ:OMER) released an update regarding the Committee for Medicinal Products for Human Use’s (CHMP) review of a marketing authorization application for the company’s narsoplimab.  This antibody targets MASP-2 to cure hematopoietic stem cell transplant-related thrombotic microangiopathy.

oatautta/Shutterstock.com

After an oral explanation meeting, Omeros stated that the CHMP adopted a negative opinion on the filing. The company plans to request a reconsideration of the opinion and seek assessment by an Ad Hoc Expert Panel, which is an independent group of external clinical and scientific specialists to be assembled by the EMA.

Later, on June 26, Brandon Folkes from H.C. Wainwright cut the price target on Omeros Corp. (NASDAQ:OMER) from $40 to $33, which still implies an adjusted upside of more than 233%. The analyst kept a Buy rating on the stock despite an unfavorable opinion on Yartemlea shared by the CHMP.

Folkes labeled this development as a short-term headwind but does not consider this to be a major hurdle for the stock’s long-term potential. Further, he pointed to the antibody’s U.S. launch as the key value driver. He highlighted that the reduced price target incorporates increased forward-looking outlays on R&D and the removal of the EU opportunity from its valuation model.

Omeros Corp. (NASDAQ:OMER) is a clinical-stage biopharmaceutical developer that specializes in the discovery and development of drugs for immunologic diseases and rare diseases. The company’s drug candidate, Narsoplimab, is intended for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy.

While we acknowledge the risk and potential of OMER as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than OMER and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None. Follow Insider Monkey on Google News.